Decision Diagnostics Announces New GenAccord!(TM),
Post# of 11803
(Total Views: 466)
Posted On: 12/14/2017 9:36:02 AM
Decision Diagnostics Announces New GenAccord!(TM), Diabetic Test Strip with First Use of Its GenPrecis!(TM) Full Spread Electrode Technology
Dec 14, 2017
OTC Disclosure & News Service
-
LOS ANGELES, CA / ACCESSWIRE / December 14, 2017 / Decision Diagnostics Corp. (OTC PINK: DECN) is a manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate!™ ("Sunshine"
diabetes test strip, the new internationally launched GenSure!™ ("Feather" diabetes test strip, and the clinical trial ready GenChoice!™ ("Ladybug" diabetes test strip.
Additionally, DECN is in the final stages of preparation for the international pre-market launch and the filing of a 510K application with the U.S. FDA for its GenChoice!™ ("Ladybug" diabetes test strips, and the company's GenPrecis!™ ("Dragonfly" Precise glucometer and diabetes test strip, a product in advanced development and designed for use by children and for general commercial sale.
Today, we are pleased to announce that the 2018 marketplace that will greet GenAccord!™ ("Bumble Bee" our newest product concept now in research and development. GenAccord!™ is the first direct outgrowth of our GenPrecis!™ full spread electro-chemistry technology. Our new test strip can work equally well either on newer technology meters or on vintage electro-chemistry meters. Our first implementation of GenAccord!™ will be a legacy family of meters with 800,000 total users (Generation 1 and Generation 2) in use worldwide. Future implementations could include several families of legacy meters manufactured by different legacy manufacturers."
We ask that all interested parties watch for our discussion.
ABOUT DECISION DIAGNOSTICS CORP.
Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 6.9 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products will shortly compete on a worldwide scale with legacy manufacturers currently selling to 65+ percent of a $12 billion market.
Forward-Looking Statements:
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of October 17, 2017, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.
CONTACT INFORMATION:
Decision Diagnostics Corp.
Keith Berman (805) 446-2973
info@decisiondiagnostics.com
www.pharmatechdirect.com
SOURCE: Decision Diagnostics Corp.
Copyright © 2017 Accesswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Dec 14, 2017
OTC Disclosure & News Service
-
LOS ANGELES, CA / ACCESSWIRE / December 14, 2017 / Decision Diagnostics Corp. (OTC PINK: DECN) is a manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate!™ ("Sunshine"
diabetes test strip, the new internationally launched GenSure!™ ("Feather" diabetes test strip, and the clinical trial ready GenChoice!™ ("Ladybug" diabetes test strip. Additionally, DECN is in the final stages of preparation for the international pre-market launch and the filing of a 510K application with the U.S. FDA for its GenChoice!™ ("Ladybug"
diabetes test strips, and the company's GenPrecis!™ ("Dragonfly" Precise glucometer and diabetes test strip, a product in advanced development and designed for use by children and for general commercial sale. Today, we are pleased to announce that the 2018 marketplace that will greet GenAccord!™ ("Bumble Bee"
our newest product concept now in research and development. GenAccord!™ is the first direct outgrowth of our GenPrecis!™ full spread electro-chemistry technology. Our new test strip can work equally well either on newer technology meters or on vintage electro-chemistry meters. Our first implementation of GenAccord!™ will be a legacy family of meters with 800,000 total users (Generation 1 and Generation 2) in use worldwide. Future implementations could include several families of legacy meters manufactured by different legacy manufacturers." We ask that all interested parties watch for our discussion.
ABOUT DECISION DIAGNOSTICS CORP.
Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 6.9 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products will shortly compete on a worldwide scale with legacy manufacturers currently selling to 65+ percent of a $12 billion market.
Forward-Looking Statements:
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of October 17, 2017, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.
CONTACT INFORMATION:
Decision Diagnostics Corp.
Keith Berman (805) 446-2973
info@decisiondiagnostics.com
www.pharmatechdirect.com
SOURCE: Decision Diagnostics Corp.
Copyright © 2017 Accesswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
(3)
(0)